Pharmaceutical company Sinclair Pharma is launching a new hyaluronic acid (HA) facial filler called MaiLi.
The company explains that MaiLi has four products in its portfolio: Precise, Define, Volume and Extreme. Precise is designed to treat fine lines, reconstruct structural defects from scar tissue, and treat the periorbital area. Define is designed for filling deep wrinkles and for volumising the lips. Volume is designed for facial volumisation and subdermal fat pad injection. Extreme is formulated with the highest concentration of HA within the MaiLi product range, and is created to sculpt and shape the face.
According to Sinclair Pharma, MaiLi patented the world’s first OxiFree technology, which preserves long molecular HA chains. The company states that the crosslinking of HA with 1,4-Butanediol diglycidyl ether (BDDE) has created a supple, spring-like gel with volume, projection power and longevity.
Chloé Antunes, Sinclair Pharma marketing manager, said, “Through identifying a sizeable gap in the market for fillers to maximise volume, suppleness and longevity combined, MaiLi utilised a unique opportunity to design a premium line of HA gels to meet this demand. When partnering with MaiLi, treatment possibilities are elevated with a premium portfolio of high-performing HA gels, promising supreme volume, suppleness, projection power and longevity, for technically-gifted professionals to refine their craft with precision and care.”